AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers, tumor-initiating cells, using our autologous cell platform. Founded in 2016 by pioneers in the stem cell industry, AIVITA utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial products and therapeutic pipeline.
AIVITA’s lead focus is on patient-specific vaccines for the treatment of advanced cancers and the prevention of COVID-19. The vaccines consist of autologous dendritic cells loaded with autologous tumor cells or SARS-CoV-2 antigens, which direct the patient’s own immune system to seek out and destroy the very cells responsible for the growth and spread of the disease. In cancer, AIVITA takes a unique pan-antigenic approach—targeting all neoantigens of tumor-initiating cells, rather than a select few — allowing the treatment to better target the cells responsible for the spread of cancer and overcome its tendency to mutate over time. In COVID-19 we target SARS-CoV-2 specific antigens with a vaccine that ships as a kit, a platform technology that can be rapidly adapted and scaled to meet emerging viral mutations.
Based on clinical trial results showing tremendous promise in eradicating tumors without harmful side effects, the cancer technology has been cleared for an upcoming US-based Phase 3 clinical trial in glioblastoma and is the subject of a US-based Phase 1B clinical trial for melanoma with checkpoint inhibitors.